Affiner les résultats

An immature B cell population from peripheral blood serves as surrogate marker for monitoring tumor angiogenesis and anti-angiogenic therapy in mouse models

Fagiani, Ernesta ; Bill, Ruben ; Pisarsky, Laura ; Ivanek, Robert ; Rüegg, Curzio ; Christofori, Gerhard

In: Angiogenesis, 2015, vol. 18, no. 3, p. 327-345

6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice

Jeanbart, Laura ; Kourtis, Iraklis ; van der Vlies, André ; Swartz, Melody ; Hubbell, Jeffrey

In: Cancer Immunology, Immunotherapy, 2015, vol. 64, no. 8, p. 1033-1046

Formation and role of exosomes in cancer

Brinton, Lindsey ; Sloane, Hillary ; Kester, Mark ; Kelly, Kimberly

In: Cellular and Molecular Life Sciences, 2015, vol. 72, no. 4, p. 659-671

Detection of HER2+ breast cancer cells using bioinspired DNA-based signal amplification

Rafiee, Sarah D. ; Kocabey, Samet ; Mayer, Michael ; List, Jonathan ; Rüegg, Curzio

In: ChemMedChem, 2020, vol. 15, no. 8, p. 661-666

Circulating tumor cells (CTC) are promising biomarkers for metastatic cancer detection and monitoring progression. However, detection of CTCs remains challenging due to their low frequency and heterogeneity. Herein, we report a bioinspired approach to detect individual cancer cells, based on a signal amplification cascade using a programmable DNA hybridization chain reaction (HCR) circuit. We...

The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity

Martin, Kea ; Müller, Philipp ; Schreiner, Jens ; Prince, Spasenija ; Lardinois, Didier ; Heinzelmann-Schwarz, Viola ; Thommen, Daniela ; Zippelius, Alfred

In: Cancer Immunology, Immunotherapy, 2014, vol. 63, no. 9, p. 925-938

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab

Meyer, Christiane ; Cagnon, Laurène ; Costa-Nunes, Carla ; Baumgaertner, Petra ; Montandon, Nicole ; Leyvraz, Loredana ; Michielin, Olivier ; Romano, Emanuela ; Speiser, Daniel

In: Cancer Immunology, Immunotherapy, 2014, vol. 63, no. 3, p. 247-257

Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy

Pretto, Francesca ; Elia, Giuliano ; Castioni, Nadia ; Neri, Dario

In: Cancer Immunology, Immunotherapy, 2014, vol. 63, no. 9, p. 901-910

The use of the EVITA algorithm for clinical assessment of novel agents used in prostate cancer, metastatic melanoma, and systemic lupus erythematosus

Szucs, Thomas ; Puri, Daniele ; Blank, Patricia

In: European Journal of Clinical Pharmacology, 2014, vol. 70, no. 8, p. 983-990

Biomarkers in renal cancer

Moch, Holger ; Srigley, John ; Delahunt, Brett ; Montironi, Rodolfo ; Egevad, Lars ; Tan, Puay

In: Virchows Archiv, 2014, vol. 464, no. 3, p. 359-365

Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer

Lan, Qiang ; Peyvandi, Sanam ; Duffey, Nathalie ; Huang, Yu-Ting ; Barras, David ; Held, Werner ; Richard, François ; Delorenzi, Mauro ; Sotiriou, Christos ; Desmedt, Christine ; Lorusso, Girieca ; Rüegg, Curzio

In: Oncogene, 2019, vol. 38, no. 15, p. 2814–2829

Neoadjuvant and adjuvant chemotherapies provide survival benefits to breast cancer patients, in particular in estrogen receptor negative (ER−) cancers, by reducing rates of recurrences. It is assumed that the benefits of (neo)adjuvant chemotherapy are due to the killing of disseminated, residual cancer cells, however, there is no formal evidence for it. Here, we provide experimental...